Comparison
Semaglutide vs Liraglutide
Weekly semaglutide compared with daily liraglutide — same family, very different injection cadence and titration pattern.
Semaglutide and Liraglutide both show up in the same conversations, but they aren't interchangeable. The table above lays the vial math side by side so you can see how concentration, doses-per-vial, and weekly cadence actually compare. The sections below walk through what each one is, how each is studied, and how each shows up in a tracked log — in plain English, no recommendations.
Tiebreakers
Where Semaglutide and Liraglutide actually diverge
| Semaglutide | Liraglutide | |
|---|---|---|
| Cadence | 1/wk | 7/wk |
| Concentration on example | 2.50 mg/mL | 2.00 mg/mL |
| Math weeks per vial | 20.0 | 0.7 |
| Category | GLP-1 | GLP-1 |
Bolded values are the higher of the two on numeric rows. Same-value rows aren't a verdict — they're shared properties.
Semaglutide vs Liraglutide: the actual decision
Cadence is the headline difference here. Liraglutide is a daily subcutaneous shot; semaglutide is weekly. Both are GLP-1 agonists with the same broad mechanism, but the half-life difference (about 13 hours for liraglutide, about a week for semaglutide) drives almost every practical difference a reader will notice in a log. A liraglutide log has 7x the injection events of a semaglutide log over the same calendar window, which has real implications for adherence, scar tissue rotation, and the texture of side-effect tracking.
Trial data put semaglutide ahead on absolute weight loss in head-to-head comparisons — STEP-8 reported about 16 percent loss at 68 weeks for semaglutide 2.4 mg weekly versus about 6 percent for liraglutide 3.0 mg daily over the same window. The gap is structural rather than dose-dependent: semaglutide's longer half-life produces steadier receptor occupancy, which is the variable most strongly correlated with weight-loss magnitude in this drug class. Liraglutide is the older, more established option; semaglutide is the more aggressive one on the loss curve.
Mechanism, cadence, and what shows up in a log
Titration on liraglutide is daily and incremental — 0.6, 1.2, 1.8, 2.4, 3.0 mg added in weekly steps. Semaglutide titrates through 0.25, 0.5, 1.0, 1.7, 2.4 mg in 4-week steps. The total ramp time is similar (about a month for both to reach a working dose, longer to top dose), but a daily versus weekly cadence changes the shape of the early-weeks log dramatically — daily users see and score side effects 7x as often, which can make liraglutide read as harsher in a log even when the absolute side-effect rate is comparable.
For tracking purposes the two molecules occupy very different ergonomic categories. A weekly shot is one calendar event; a daily shot is a ritual that needs to land in roughly the same window every day. The calculator pages linked below handle the unit math for either, and the dose-per-vial column on the table above shows how a single vial stretches across the two cadences at the example vial size.
Semaglutide vs Liraglutide: the numbers, side by side
Start with what actually goes into a syringe. The example Semaglutide vial on this site reconstitutes 5 mg in 2 mL of bacteriostatic water — about 2.50 mg per mL, which yields roughly 20 doses at the 0.25 mg example and lasts about 20.0 weeks at 1 dose per week. The example Liraglutide vial reconstitutes 6 mg in 3 mL (2.00 mg/mL), which yields about 5 doses at 1.2 mg and stretches roughly 0.7 weeks at 7 doses per week. Those numbers are the starting point most people forget to write down, and they decide everything downstream — refill timing, unit count on the syringe barrel, and whether a 30-mL bac-water bottle stretches across one vial or two.
Category context matters too. Both Semaglutide and Liraglutide sit in the GLP-1 bucket, so the head-to-head questions readers bring here are usually about cadence, titration step size, and which of the two molecules logs more cleanly inside a longer protocol rather than a from-scratch category choice. Cadence helps frame the rest: Semaglutide is logged about 1× per week in the example schedule, Liraglutide about 7×.
The single most-asked-about mistake on each page is worth surfacing here, because they rarely overlap. On the Semaglutide side: Switching to a new vial of the same peptide and reusing the old unit count without re-running the calculation against the new vial's diluent volume. On the Liraglutide side: Failing to titrate the dose up slowly. Both are the kind of thing a tracked log catches early and an untracked routine catches late.
By adding a measured volume of bacteriostatic water to the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves into a clear solution. The exact diluent volume is up to the user; common choices for a 5 mg vial are 1, 2, or 3 mL.
Saxenda and Victoza contain the same active ingredient, Liraglutide. However, they are used for different purposes and at different maximum doses. Saxenda is generally used for weight management and has a higher target dose (3.0 mg), while Victoza is primarily used for blood sugar management in type 2 diabetes and has a lower target dose (1.8 mg).
The calculator pages linked below let you swap your own vial size, diluent volume, and dose into the same math — these example numbers exist so the comparison renders with concrete figures instead of placeholders.
Frequently asked questions about Semaglutide vs Liraglutide
How is semaglutide reconstituted?
How many units of semaglutide are in 0.25 mg?
Why is semaglutide dosed weekly?
What's the difference between Saxenda and Victoza?
Why is Liraglutide injected daily instead of weekly?
What are the commonly reported side effects?
Related on Peptide Pilot
- Open
Semaglutide reference
Overview, mechanism, mistakes, and FAQs.
- Open
Liraglutide reference
Overview, mechanism, mistakes, and FAQs.
- Open
Semaglutide calculators
Reconstitution, dose, mg ↔ units, vial duration.
- Open
Liraglutide calculators
Reconstitution, dose, mg ↔ units, vial duration.
- Open
All peptide comparisons
Browse the full list of side-by-side reference pages.
- Open
Semaglutide vs Tirzepatide
Two weekly GLP-1 family shots people compare for weight loss and blood-sugar steadiness — different receptor coverage, different dosing ramp.
- Open
Semaglutide vs Retatrutide
An established weekly GLP-1 next to a newer triple-agonist studied for larger weight-loss numbers in early trials.
- Open
Liraglutide vs Tirzepatide
Daily liraglutide alongside weekly tirzepatide — pace of dosing, receptor coverage, and how each fits a tracked log.